Pheochromocytoma

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search


Section editor
Jeenavarghese.jpg
Jeena M. Varghese, MBBS
Houston, TX

LinkedIn
2 regimens on this page
3 variants on this page


Guidelines

NCCN

All lines of therapy

Cyclophosphamide, Dacarbazine, Vincristine

back to top

CVD: Cyclophosphamide, Vincristine, Dacarbazine

Regimen

Study Evidence
Averbuch et al. 1988 Pilot, <20 pts

Chemotherapy

21-day cycles

References

  1. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988 Aug 15;109(4):267-73. link to original article contains protocol PubMed

131I-Metaiodobenzylguanidine (131I-MIBG)

back to top

Also known as m-[131I]iodobenzylguanidine ([131I]MIBG).

Variant #1

Study Evidence
Rose et al. 2003 Pilot, <20 pts

Patients underwent stem cell harvest prior to treatment in case autologous stem cell infusion was needed.

Radiotherapy

  • 131I-Metaiodobenzylguanidine (131I-MIBG) 12 to 18 mCi/kg (maximum single dose of 850 mCi) IV over 2 hours once on day 1

Supportive medications

  • Intravenous fluids started 12 hours before 131I-MIBG administration.
  • Potassium iodide (KI) 6 mg/kg PO once at least 2 hours prior to 131I-MIBG, then potassium iodide (KI) 0.88 mg/kg PO Q4H x 7 days, then potassium iodide (KI) 1 mg/kg PO (frequency not specified) "for 45 days after the infusion."
  • Potassium perchlorate 8 mg/kg once at least 2 hours prior to 131I-MIBG, then potassium perchlorate 2 mg/kg PO Q6H x 5 days.

"Repeat 131I-MIBG treatments were administered on a case-by-case basis in an effort to improve the overall response"

Variant #2

Study Evidence
Krempf et al. 1991 Pilot, <20 pts

Radiotherapy

  • m-[131I]iodobenzylguanidine ([131I]MIBG) 740 megabequerel/mg every 3 months

References

  1. Krempf M, Lumbroso J, Mornex R, Brendel AJ, Wemeau JL, Delisle MJ, Aubert B, Carpentier P, Fleury-Goyon MC, Gibold C et al. Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 1991 Feb;72(2):455-61. link to original article contains protocol PubMed
  2. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer. 2003 Jul 15;98(2):239-48. link to original article contains verified protocol PubMed